2.79
+0.03(+1.09%)
Currency In USD
| Previous Close | 2.76 |
| Open | 2.77 |
| Day High | 2.84 |
| Day Low | 2.72 |
| 52-Week High | 4.12 |
| 52-Week Low | 0.91 |
| Volume | 1.48M |
| Average Volume | 2.46M |
| Market Cap | 250.88M |
| PE | -0.98 |
| EPS | -2.84 |
| Moving Average 50 Days | 2.7 |
| Moving Average 200 Days | 1.88 |
| Change | 0.03 |
If you invested $1000 in Editas Medicine, Inc. (EDIT) since IPO date, it would be worth $153.3 as of September 08, 2025 at a share price of $2.79. Whereas If you bought $1000 worth of Editas Medicine, Inc. (EDIT) shares 5 years ago, it would be worth $95.38 as of September 08, 2025 at a share price of $2.79.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
GlobeNewswire Inc.
Sep 02, 2025 11:00 AM GMT
EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into second quarter of 2027 Company-sponsored webinar on
Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
GlobeNewswire Inc.
Aug 28, 2025 8:01 PM GMT
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will host a webinar on Tuesday,
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
GlobeNewswire Inc.
Jun 12, 2025 6:01 AM GMT
Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports development of a novel, in vivo approac